{"title": "Esclerosis-Multiple-MSblog", "author": "Carlos Navas", "url": "https://neuronavasms.blogspot.com/2019/09/", "hostname": "blogspot.com", "description": "Un blog sobre Enfermedad Desmielinizante , Esclerosis Multiple , Neuromielitis Optica , Neurologo Bogota, Carlos Navas, Neurologia", "sitename": "neuronavasms.blogspot.com", "date": "2019-09-30", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "A continuacion dos articulos recientes sobre el signo de la vena central y su utilidad para el diagnostico diferencial y biomarcador diagnostico por imagen en Esclerosis Multiple\nA trav\u00e9s de los a\u00f1os , la imagen por resonancia magn\u00e9tica (IRM) se ha convertido en una herramienta indispensable para el diagnostico de la Esclerosis M\u00faltiple (EM). Sin embargo, los criterios de resonancia magn\u00e9tica actuales para el diagn\u00f3stico de Esclerosis M\u00faltiple tienen una sensibilidad y especificidad que no son absolutas .\nComo un medio para distinguir las lesiones de Esclerosis M\u00faltiple de las anormalidades de la sustancia blanca que surgen de otras enfermedades, se ha propuesto la identificaci\u00f3n de una vena que atraviesa el centro de una lesi\u00f3n como una herramienta de diagn\u00f3stico porque la desmielinizaci\u00f3n inflamatoria en la sustancia blanca de la Esclerosis M\u00faltiple es perivenular (\n[Tallantyre EC, et al Neurology 2011](https://n.neurology.org/content/76/6/534?ijkey=82939176f44c64c4dc8fd395ea6afb11eea55e64&keytype2=tf_ipsecsha)).\nEl signo de la vena central (CVS) se ha propuesto recientemente como un nuevo biomarcador de resonancia magn\u00e9tica para mejorar la precisi\u00f3n y la velocidad del diagn\u00f3stico de Esclerosis M\u00faltiple.\nLa evidencia indica que la presencia de CVS en lesiones individuales puede diferenciar con precisi\u00f3n la Esclerosis M\u00faltiple de otras enfermedades que la imitan.\nEl potencial para que este marcador se use en el diagn\u00f3stico de Esclerosis M\u00faltiple ha sido avanzado por los desarrollos recientes en las secuencias de pulso de im\u00e1genes de IRM, que han permitido obtener im\u00e1genes detalladas de las venas en el cerebro (\n[Campion T, et al. Eur Radiol 201](https://link.springer.com/article/10.1007/s00330-017-4822-z)7).\nUsando estas secuencias, los investigadores han proporcionado pruebas contundentes de que proporciones m\u00e1s altas de lesiones de Esclerosis M\u00faltiple muestran el signo de la vena central (CVS) en comparaci\u00f3n con las lesiones resultantes de otros procesos de enfermedad com\u00fanmente confundidos con Esclerosis M\u00faltiple. Este hallazgo se ha demostrado para el desorden del espectro de neuromielitis \u00f3ptica, enfermedades autoinmunes sist\u00e9micas, enfermedad de vasos peque\u00f1os cerebrales, s\u00edndrome de Susac y migra\u00f1a. Si bien a\u00fan es necesaria una mayor replicaci\u00f3n en un entorno prospectivo, una alta proporci\u00f3n de lesiones cerebrales por IRM que demuestran el CVS parecen tener potencial como biomarcadores con alta especificidad para la Esclerosis M\u00faltiple.\nDworkin JD y Ontaneda D et al introdujeron un algoritmo para la determinaci\u00f3n autom\u00e1tica del CVS en las lesiones de la sustancia blanca y presenta un biomarcador de diagn\u00f3stico a nivel de paciente totalmente automatizado. (\n[American Journal of Neuroradiology October 2018](http://www.ajnr.org/content/39/10/1806.long)).\nMaggi P y Filippi M et al.\n[Ann Neurol 2018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901412/), Publicaron el resultado de su estudio donde la resonancia magn\u00e9tica basada en la susceptibilidad es una herramienta \u00fatil cuando se intenta diferenciar la Esclerosis M\u00faltiplede las vasculopat\u00edas inflamatorias que afectan al SNC.\n[Mult Scler.](https://www.ncbi.nlm.nih.gov/pubmed/31536435) 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031. [Epub ahead of print]\nThe \"central vein sign\" in patients with diagnostic \"red flags\" for multiple sclerosis: A prospective multicenter 3T study.\nMaggi P, Absinta M, Sati P, Perrotta G, Massacesi L, Dachy B, Pot C, Meuli R, Reich DS, Filippi M, Pasquier RD, Th\u00e9audin M.\nThe central vein sign (CVS) has been shown to help in the differential diagnosis of multiple sclerosis (MS), but most prior studies are retrospective.\nTo prospectively assess the diagnostic predictive value of the CVS in diagnostically difficult cases.\nIn this prospective multicenter study, 51 patients with suspected MS who had clinical, imaging, or laboratory \"red flags\" (i.e. features atypical for MS) underwent 3T fluid-attenuated inversion recovery (FLAIR*) magnetic resonance imaging (MRI) for CVS assessment. After the diagnostic work-up, expert clinicians blinded to the results of the CVS assessment came to a clinical diagnosis. The value of the CVS to prospectively predict an MS diagnosis was assessed.\nOf the 39 patients who received a clinical diagnosis by the end of the study, 27 had MS and 12 received a non-MS diagnosis that included systemic lupus erythematosus, sarcoidosis, migraine, Sj\u00f6gren disease, SPG4-spastic-paraparesis, neuromyelitis optica, and Susac syndrome. The percentage of perivenular lesions was higher in MS (median = 86%) compared to non-MS (median = 21%; p < 0.0001) patients. A 40% perivenular lesion cutoff was associated with 97% accuracy and a 96% positive/100% negative predictive value.\nThe CVS detected on 3T FLAIR* images can accurately predict an MS diagnosis in patients suspected to have MS, but with atypical clinical, laboratory, and imaging features.\nEl \"signo de la vena central\" en pacientes con diagn\u00f3stico de \"se\u00f1ales de alerta\" para la Esclerosis M\u00faltiple: un estudio prospectivo multic\u00e9ntrico 3T.\nMaggi P, Absinta M, Sati P, Perrotta G, Massacesi L, Dachy B, Pot C, Meuli R, Reich DS, Filippi M, Pasquier RD, Th\u00e9audin M.\nSe ha demostrado que el signo de la vena central (CVS) ayuda en el diagn\u00f3stico diferencial de la Esclerosis M\u00faltiple (EM), pero la mayor\u00eda de los estudios anteriores son retrospectivos.\nEvaluar prospectivamente el valor predictivo diagn\u00f3stico del CVS en casos de diagn\u00f3stico dif\u00edcil.\nEn este estudio prospectivo multic\u00e9ntrico, 51 pacientes con sospecha de EM que ten\u00edan \"se\u00f1ales de alerta\" cl\u00ednicas, de im\u00e1genes o de laboratorio (es decir, caracter\u00edsticas at\u00edpicas para la EM) se sometieron a im\u00e1genes de resonancia magn\u00e9tica (MRI) de recuperaci\u00f3n de inversi\u00f3n atenuada por l\u00edquido (FLAIR *) 3T para la evaluaci\u00f3n del CVS . Despu\u00e9s de la evaluaci\u00f3n diagn\u00f3stica, los m\u00e9dicos expertos cegados a los resultados de la evaluaci\u00f3n CVS llegaron a un diagn\u00f3stico cl\u00ednico. Se evalu\u00f3 el valor del CVS para predecir prospectivamente un diagn\u00f3stico de EM.\nDe los 39 pacientes que recibieron un diagn\u00f3stico cl\u00ednico al final del estudio, 27 ten\u00edan EM y 12 recibieron un diagn\u00f3stico sin EM que inclu\u00eda lupus eritematoso sist\u00e9mico, sarcoidosis, migra\u00f1a, enfermedad de Sj\u00f6gren, paraparesia esp\u00e1stica SPG4, neuromielitis \u00f3ptica y S\u00edndrome de Susac El porcentaje de lesiones perivenulares fue mayor en pacientes con EM (mediana = 86%) en comparaci\u00f3n con pacientes sin EM (mediana = 21%; p < 0,0001). Un l\u00edmite de lesi\u00f3n perivenular del 40% se asoci\u00f3 con una precisi\u00f3n del 97% y un valor predictivo positivo del 96% / negativo del 100%.\nEl CVS detectado en las im\u00e1genes 3T FLAIR * puede predecir con precisi\u00f3n un diagn\u00f3stico de EM en pacientes con sospecha de EM, pero con caracter\u00edsticas cl\u00ednicas, de laboratorio y de im\u00e1genes at\u00edpicas.\n[JAMA Neurol.](https://www.ncbi.nlm.nih.gov/pubmed/31424490) 2019 Aug 19. doi: 10.1001/jamaneurol.2019.2478. [Epub ahead of print]\nEvaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.\nSinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Kappos L, Montalban X, Rovira \u00c0, Evangelou N, Wuerfel J; MAGNIMS Study Group.\nThe central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies. The diagnostic value of the central vein sign in a multicenter setting with a variety of clinical 3 tesla (T) MRI protocols, however, remains unknown.\nTo evaluate the sensitivity and specificity of various central vein sign lesion criteria for differentiating MS from non-MS conditions using 3T brain MRI with various commonly used pulse sequences.\nDESIGN, SETTING, AND PARTICIPANTS:\nThis large multicenter, cross-sectional study enrolled participants (n = 648) of ongoing observational studies and patients included in neuroimaging research databases of 8 neuroimaging centers in Europe. Patient enrollment and MRI data collection were performed between January 1, 2010, and November 30, 2016. Data analysis was conducted between January 1, 2016, and April 30, 2018. Investigators were blinded to participant diagnosis by a novel blinding procedure.\nMAIN OUTCOMES AND MEASURES:\nOccurrence of central vein sign was detected on 3T T2*-weighted or susceptibility-weighted imaging. Sensitivity and specificity were assessed for these MRI sequences and for different central vein sign lesion criteria, which were defined by the proportion of lesions with central vein sign or by absolute numbers of lesions with central vein sign.\nA total of 606 participants were included in the study after exclusion of 42 participants. Among the 606 participants, 413 (68.2%) were women. Patients with clinically isolated syndrome and relapsing-remitting MS (RRMS) included 235 women (66.6%) and had a median (range) age of 37 (14.7-61.4) years, a median (range) disease duration of 2 (0-33) years, and a median (range) Expanded Disability Status Scale score of 1.5 (0-6.5). Patients without MS included 178 women (70.4%) and had a median (range) age of 54 (18-83) years. A total of 4447 lesions were analyzed in a total of 487 patients: 690 lesions in 98 participants with clinically isolated syndrome, 2815 lesions in 225 participants with RRMS, 54 lesions in 13 participants with neuromyelitis optica spectrum disorder, 54 lesions in 14 participants with systemic lupus erythematosus, 121 lesions in 29 participants with migraine or cluster headache, 240 lesions in 20 participants with diabetes, and 473 lesions in 88 participants with other types of small-vessel disease. The sensitivity was 68.1% and specificity was 82.9% for distinguishing MS from not MS using a 35% central vein sign proportion threshold. The 3 central vein sign lesion criteria had a sensitivity of 61.9% and specificity of 89.0%. Sensitivity was higher when an optimized T2*-weighted sequence was used.\nCONCLUSIONS AND RELEVANCE:\nIn this study, use of the central vein sign at 3T MRI yielded a high specificity and a moderate sensitivity in differentiating MS from not MS; international, multicenter studies may be needed to ascertain whether the central vein sign-based criteria can accurately detect MS.\nJAMA Neurol. 2019 19 de agosto. Doi: 10.1001 / jamaneurol.2019.2478. [Epub antes de imprimir]\nEvaluaci\u00f3n del signo de la vena central como un biomarcador de diagn\u00f3stico por im\u00e1genes en la Esclerosis M\u00faltiple.\nSinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Kappos L, Montalban X, Rovira \u00c0, Evangelou N, Wuerfel J; MAGNIMS Study Group.\nEl signo de la vena central se ha propuesto como un biomarcador de imagen espec\u00edfico para distinguir entre la esclerosis m\u00faltiple (EM) y no la EM, principalmente en base a los resultados de los estudios de im\u00e1genes de resonancia magn\u00e9tica de campo ultra alto (MRI). Sin embargo, el valor de diagn\u00f3stico del signo de la vena central en un entorno multic\u00e9ntrico con una variedad de protocolos cl\u00ednicos de resonancia magn\u00e9tica de 3 teslas (T) sigue siendo desconocido.\nEvaluar la sensibilidad y la especificidad de varios criterios de lesi\u00f3n de signo de vena central para diferenciar la EM de las afecciones que no son EM utilizando resonancia magn\u00e9tica cerebral 3T con varias secuencias de pulso de uso com\u00fan.\nDISE\u00d1O, AJUSTE Y PARTICIPANTES:\nEste gran estudio transversal multic\u00e9ntrico incluy\u00f3 participantes (n = 648) de estudios observacionales en curso y pacientes incluidos en bases de datos de investigaci\u00f3n de neuroimagen de 8 centros de neuroimagen en Europa. La inscripci\u00f3n de pacientes y la recopilaci\u00f3n de datos de MRI se realizaron entre el 1 de enero de 2010 y el 30 de noviembre de 2016. El an\u00e1lisis de datos se realiz\u00f3 entre el 1 de enero de 2016 y el 30 de abril de 2018. Los investigadores fueron cegados al diagn\u00f3stico de los participantes mediante un nuevo procedimiento de cegamiento.\nPRINCIPALES RESULTADOS Y MEDIDAS:\nLa aparici\u00f3n del signo de la vena central se detect\u00f3 en im\u00e1genes 3T T2 * o ponderadas por susceptibilidad. La sensibilidad y la especificidad se evaluaron para estas secuencias de IRM y para diferentes criterios de lesi\u00f3n de signo de vena central, que se definieron por la proporci\u00f3n de lesiones con signo de vena central o por el n\u00famero absoluto de lesiones con signo de vena central.\nUn total de 606 participantes fueron incluidos en el estudio despu\u00e9s de la exclusi\u00f3n de 42 participantes. Entre los 606 participantes, 413 (68,2%) eran mujeres. Los pacientes con s\u00edndrome cl\u00ednico aislado y EM recurrente-remitente (EMRR) incluyeron a 235 mujeres (66,6%) y ten\u00edan una mediana de edad (rango) de 37 (14,7-61,4) a\u00f1os, una mediana (rango) de duraci\u00f3n de la enfermedad de 2 (0-33). ) a\u00f1os y una mediana (rango) puntaje ampliado de la escala de estado de discapacidad de 1.5 (0-6.5). Los pacientes sin EM incluyeron 178 mujeres (70.4%) y ten\u00edan una mediana (rango) de edad de 54 (18-83) a\u00f1os. Se analizaron un total de 4447 lesiones en un total de 487 pacientes: 690 lesiones en 98 participantes con s\u00edndrome cl\u00ednico aislado, 2815 lesiones en 225 participantes con EMRR, 54 lesiones en 13 participantes con desorden del espectro \u00f3ptico de neuromielitis, 54 lesiones en 14 participantes con s\u00edndrome sist\u00e9mico lupus eritematoso, 121 lesiones en 29 participantes con migra\u00f1a o cefalea en racimos, 240 lesiones en 20 participantes con diabetes y 473 lesiones en 88 participantes con otros tipos de enfermedad peque\u00f1o vaso. La sensibilidad fue del 68,1% y la especificidad del 82,9% para distinguir la EM de la no EM utilizando un umbral de proporci\u00f3n de signos de vena central del 35%.\nLos 3 criterios de lesi\u00f3n del signo vena central ten\u00edan una sensibilidad del 61,9% y una especificidad del 89,0%. La sensibilidad fue mayor cuando se utiliz\u00f3 una secuencia ponderada T2 * optimizada.\nCONCLUSIONES Y PERTINENCIA:\nEn este estudio, el uso del signo de la vena central en la resonancia magn\u00e9tica 3T produjo una alta especificidad y una sensibilidad moderada en la diferenciaci\u00f3n de la EM de la no EM; Es posible que se necesiten estudios internacionales multic\u00e9ntricos para determinar si los criterios basados en signos de vena central pueden detectar con precisi\u00f3n la EM.\nEspero les sea \u00fatil la informacion .\nNeurologia Bogota\nNeurologo Enfermedad Desmielinizante", "language": null, "image": null, "pagetype": null, "links": ["https://neuronavasms.blogspot.com/?m=0", null, "https://neuronavasms.blogspot.com/2019/09/conferencia-relacion-recaidas-y.html?m=0", "https://office.com", "https://office.com/webapps", "https://1.bp.blogspot.com/-iKwnOsnUJNU/WMVROwCkx8I/AAAAAAAAASE/TSXrusi08ywkvwaSz7rRoBI9zKuFKlkVQCPcBGAYYCw/s1600/brain.jpg", "https://www.blogger.com/profile/00979658930962324258", "https://neuronavasms.blogspot.com/2019/09/conferencia-relacion-recaidas-y.html?m=0", "https://neuronavasms.blogspot.com/2019/09/conferencia-relacion-recaidas-y.html?m=0#comment-form", "https://www.blogger.com/email-post.g?blogID=6148193344149753136&postID=5171976252454660872", "https://www.blogger.com/post-edit.g?blogID=6148193344149753136&postID=5171976252454660872&from=pencil", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5171976252454660872&target=email", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5171976252454660872&target=blog", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5171976252454660872&target=twitter", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5171976252454660872&target=facebook", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5171976252454660872&target=pinterest", "https://maps.google.com/maps?q=Latin+America@-4.4420385,-61.32685350000003&z=10", "https://www.blogger.com/profile/00979658930962324258", null, "https://neuronavasms.blogspot.com/2019/09/el-signo-de-la-vena-central-en.html?m=0", "https://1.bp.blogspot.com/-OaeRvAjUyO8/XYgzMKSE81I/AAAAAAAADf4/09qqMWQCDAsuZwPan8LX4H79Bjs9tcsYACLcBGAsYHQ/s1600/Lupa.jpg", "https://n.neurology.org/content/76/6/534?ijkey=82939176f44c64c4dc8fd395ea6afb11eea55e64&keytype2=tf_ipsecsha", "https://www.nature.com/articles/nrneurol.2016.166", "https://link.springer.com/article/10.1007/s00330-017-4822-z", "http://www.ajnr.org/content/39/10/1806.long", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901412/", "https://www.ncbi.nlm.nih.gov/pubmed/31536435", "https://www.ncbi.nlm.nih.gov/pubmed/31424490", "https://1.bp.blogspot.com/-iKwnOsnUJNU/WMVROwCkx8I/AAAAAAAAASE/TSXrusi08ywkvwaSz7rRoBI9zKuFKlkVQCPcBGAYYCw/s1600/brain.jpg", "http://feeds.feedburner.com/Esclerosis-multiple-msblog", "https://feedburner.google.com/fb/a/mailverify?uri=Esclerosis-multiple-msblog", "https://www.blogger.com/profile/00979658930962324258", "https://neuronavasms.blogspot.com/2019/09/el-signo-de-la-vena-central-en.html?m=0", "https://neuronavasms.blogspot.com/2019/09/el-signo-de-la-vena-central-en.html?m=0#comment-form", "https://www.blogger.com/email-post.g?blogID=6148193344149753136&postID=6507888553238761297", "https://www.blogger.com/post-edit.g?blogID=6148193344149753136&postID=6507888553238761297&from=pencil", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=6507888553238761297&target=email", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=6507888553238761297&target=blog", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=6507888553238761297&target=twitter", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=6507888553238761297&target=facebook", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=6507888553238761297&target=pinterest", "https://maps.google.com/maps?q=Latin+America@-4.4420385,-61.32685350000003&z=10", "https://www.blogger.com/profile/00979658930962324258", null, "https://neuronavasms.blogspot.com/2019/09/highlights-ectrims-2019-estocolmo.html?m=0", "https://1.bp.blogspot.com/-rBmKJtUeTqU/XX66YM0yNFI/AAAAAAAADfk/8a2XNTaKP1UkHlEKVQRzjPJidS1vQzb-QCEwYBhgL/s1600/csm_49124_ECTRIMS_Titel_Website_2019_fbc6945e35.png", "https://1.bp.blogspot.com/-iKwnOsnUJNU/WMVROwCkx8I/AAAAAAAAASE/TSXrusi08ywkvwaSz7rRoBI9zKuFKlkVQCPcBGAYYCw/s1600/brain.jpg", "http://feeds.feedburner.com/Esclerosis-multiple-msblog", "https://feedburner.google.com/fb/a/mailverify?uri=Esclerosis-multiple-msblog", "https://www.blogger.com/profile/00979658930962324258", "https://neuronavasms.blogspot.com/2019/09/highlights-ectrims-2019-estocolmo.html?m=0", "https://neuronavasms.blogspot.com/2019/09/highlights-ectrims-2019-estocolmo.html?m=0#comment-form", "https://www.blogger.com/email-post.g?blogID=6148193344149753136&postID=4279887092408864268", "https://www.blogger.com/post-edit.g?blogID=6148193344149753136&postID=4279887092408864268&from=pencil", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=4279887092408864268&target=email", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=4279887092408864268&target=blog", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=4279887092408864268&target=twitter", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=4279887092408864268&target=facebook", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=4279887092408864268&target=pinterest", "https://maps.google.com/maps?q=Latin+America@-4.4420385,-61.32685350000003&z=10", "https://www.blogger.com/profile/00979658930962324258", null, "https://neuronavasms.blogspot.com/2019/09/inmunonutricion-en-esclerosis-multiple.html?m=0", "https://1.bp.blogspot.com/-zeLm0sjrKQw/Wpy9azeFZOI/AAAAAAAAB5Q/U2VTW0kiA7gv-3whAikX-btcYQQZNUmfgCPcBGAYYCw/s1600/6500803-thumb.jpg", "https://office.com", "https://office.com/webapps", "https://www.blogger.com/profile/00979658930962324258", "https://neuronavasms.blogspot.com/2019/09/inmunonutricion-en-esclerosis-multiple.html?m=0", "https://neuronavasms.blogspot.com/2019/09/inmunonutricion-en-esclerosis-multiple.html?m=0#comment-form", "https://www.blogger.com/email-post.g?blogID=6148193344149753136&postID=8975973390182454588", "https://www.blogger.com/post-edit.g?blogID=6148193344149753136&postID=8975973390182454588&from=pencil", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=8975973390182454588&target=email", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=8975973390182454588&target=blog", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=8975973390182454588&target=twitter", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=8975973390182454588&target=facebook", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=8975973390182454588&target=pinterest", "https://www.blogger.com/profile/00979658930962324258", null, "https://neuronavasms.blogspot.com/2019/09/infecciones-prevenibles-por-vacunacion.html?m=0", "https://1.bp.blogspot.com/-kphgQ0E__mE/XWxIUYqSSrI/AAAAAAAADek/yNDpPCihT8QFdzt3VqSyNjVbI4ThGaTFgCEwYBhgL/s1600/860_vaccine_explainer.png", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Practice+guideline+update+summary%3A+Vaccine-preventable+infections+and+immunization+in+multiple+sclerosis", "https://n.neurology.org/content/neurology/early/2019/08/28/WNL.0000000000008157.full.pdf", "https://www.ncbi.nlm.nih.gov/pubmed/?term=Practice+guideline+update+summary%3A+Vaccine-preventable+infections+and+immunization+in+multiple+sclerosis", "https://n.neurology.org/content/neurology/early/2019/08/28/WNL.0000000000008157.full.pdf", "https://www.cdc.gov/vaccines/schedules/", "https://jamanetwork.com/journals/jama/fullarticle/2748767", "https://1.bp.blogspot.com/-iKwnOsnUJNU/WMVROwCkx8I/AAAAAAAAASE/TSXrusi08ywkvwaSz7rRoBI9zKuFKlkVQCPcBGAYYCw/s1600/brain.jpg", "https://www.blogger.com/profile/00979658930962324258", "https://neuronavasms.blogspot.com/2019/09/infecciones-prevenibles-por-vacunacion.html?m=0", "https://neuronavasms.blogspot.com/2019/09/infecciones-prevenibles-por-vacunacion.html?m=0#comment-form", "https://www.blogger.com/email-post.g?blogID=6148193344149753136&postID=5060933943494350010", "https://www.blogger.com/post-edit.g?blogID=6148193344149753136&postID=5060933943494350010&from=pencil", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5060933943494350010&target=email", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5060933943494350010&target=blog", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5060933943494350010&target=twitter", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5060933943494350010&target=facebook", "https://www.blogger.com/share-post.g?blogID=6148193344149753136&postID=5060933943494350010&target=pinterest", "https://maps.google.com/maps?q=Latin+America@-4.4420385,-61.32685350000003&z=10", "https://www.blogger.com/profile/00979658930962324258", "https://neuronavasms.blogspot.com/search?updated-max=2019-10-06T20:10:00-05:00&max-results=1&reverse-paginate=true&m=0", "https://neuronavasms.blogspot.com/search?updated-max=2019-09-01T20:00:00-05:00&max-results=1&m=0", "https://neuronavasms.blogspot.com/?m=0", "https://neuronavasms.blogspot.com/2019/09/?m=1", "https://neuronavasms.blogspot.com/feeds/posts/default", "https://www.blogger.com/profile/00979658930962324258", "https://www.blogger.com/profile/00979658930962324258", "https://www.blogger.com/profile/00979658930962324258", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/09/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/07/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/06/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/05/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/04/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/03/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/02/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2023/01/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2022/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2022/09/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2022/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/11/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/10/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/09/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/06/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/05/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/04/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/03/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/02/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2021/01/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/12/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/11/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/10/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/09/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/07/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/06/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/05/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/04/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/03/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/02/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2020/01/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/12/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/11/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/10/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/09/?m=0", "https://neuronavasms.blogspot.com/2019/09/conferencia-relacion-recaidas-y.html?m=0", "https://neuronavasms.blogspot.com/2019/09/el-signo-de-la-vena-central-en.html?m=0", "https://neuronavasms.blogspot.com/2019/09/highlights-ectrims-2019-estocolmo.html?m=0", "https://neuronavasms.blogspot.com/2019/09/inmunonutricion-en-esclerosis-multiple.html?m=0", "https://neuronavasms.blogspot.com/2019/09/infecciones-prevenibles-por-vacunacion.html?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/07/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/06/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/05/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/04/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/03/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/02/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2019/01/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/12/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/11/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/10/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/09/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/07/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/06/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/05/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/04/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/03/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/02/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2018/01/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/08/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/07/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/06/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/05/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/04/?m=0", "javascript:void(0)", "https://neuronavasms.blogspot.com/2017/03/?m=0", "https://goo.gl/maps/8SkxJF9MpMM2", "https://www.waze.com/ul?ll=4.64805300%2C-74.10653000&navigate=yes&zoom=16", "https://www.neurologosclinicacolombia.com", "//www.youtube.com/c/CarlosTutoNavasneuroms", "https://neuronavasms.blogspot.com/p/httpsdrive.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_73.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_34.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_28.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_66.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_67.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_91.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_57.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_83.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_33.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_64.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_65.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_87.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_44.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_22.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_92.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_47.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_48.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_14.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_39.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_86.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_55.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_93.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_7.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_78.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_10.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_72.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_43.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_62.html?m=0", "https://neuronavasms.blogspot.com/p/treatment-algorithm-for-multiple.html?m=0", "https://neuronavasms.blogspot.com/p/esto-es-un-documento-de-microsoft.html?m=0", "https://neuronavasms.blogspot.com/p/patient-profile-for-high-efficacy.html?m=0", "https://neuronavasms.blogspot.com/p/enfermedad-sustancia-blanca.html?m=0", "https://neuronavasms.blogspot.com/p/neuritis-optica-en.html?m=0", "https://neuronavasms.blogspot.com/p/esto-es-un-documento-de-microsoft_6.html?m=0", "https://neuronavasms.blogspot.com/p/encuesta.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_25.html?m=0", "https://neuronavasms.blogspot.com/p/lo-destacado-en-ectrims-2018-sobre.html?m=0", "https://neuronavasms.blogspot.com/p/interacciones-entre-indice-inflamatorio.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_24.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_52.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_90.html?m=0", "https://neuronavasms.blogspot.com/p/webinar-latam-complicaciones-de-dmt-en.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_8.html?m=0", "https://neuronavasms.blogspot.com/p/dieta-y-esclerosis-multiple.html?m=0", "https://neuronavasms.blogspot.com/p/comparto-la-taller-que-se-realiza-en-el.html?m=0", "https://neuronavasms.blogspot.com/p/alem-2017-conferencia.html?m=0", "https://neuronavasms.blogspot.com/p/dia-mundial-esclerosis-multiple-31-de.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_4.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_16.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page.html?m=0", "https://neuronavasms.blogspot.com/p/recomendaciones.html?m=0", "https://www.neurologosclinicacolombia.com", "https://neuronavasms.blogspot.com/p/asociacion-de-patrones-dieteticos-con.html?m=0", "https://neuronavasms.blogspot.com/p/jama.html?m=0", "https://neuronavasms.blogspot.com/p/lo-destacado-en-ectrims-2018-sobre.html?m=0", "https://neuronavasms.blogspot.com/p/dieta-y-esclerosis-multiple.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_18.html?m=0", "https://neuronavasms.blogspot.com/p/la-intervencion-nutricional-como-parte.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_11.html?m=0", "https://neuronavasms.blogspot.com/p/blog-page_12.html?m=0", "https://neuronavasms.blogspot.com/p/interacciones-entre-indice-inflamatorio.html?m=0", "https://neuronavasms.blogspot.com/2020/03/coronavirus-y-enfermedad-desmielinizante.html?m=0", "https://neuronavasms.blogspot.com/2018/09/existe-relacion-entre-implantes-y.html?m=0", "https://neuronavasms.blogspot.com/2018/10/criterios-mcdonald-2017-y-el-tiempo-de.html?m=0", "https://neuronavasms.blogspot.com/2018/04/resumen-de-recomendaciones-de-guias-de.html?m=0", "https://neuronavasms.blogspot.com/2018/07/desorden-del-espectro-de-anticuerpos.html?m=0", "https://www.netvibes.com/subscribe.php?url=https%3A%2F%2Fneuronavasms.blogspot.com%2Ffeeds%2Fposts%2Fdefault", "https://add.my.yahoo.com/content?url=https%3A%2F%2Fneuronavasms.blogspot.com%2Ffeeds%2Fposts%2Fdefault", "https://neuronavasms.blogspot.com/feeds/posts/default", "https://www.netvibes.com/subscribe.php?url=https%3A%2F%2Fneuronavasms.blogspot.com%2Ffeeds%2Fcomments%2Fdefault", "https://add.my.yahoo.com/content?url=https%3A%2F%2Fneuronavasms.blogspot.com%2Ffeeds%2Fcomments%2Fdefault", "https://neuronavasms.blogspot.com/feeds/comments/default", "https://www.facebook.com/carlos.navas.54584982", "https://twitter.com/neuronavasms", "hhttps://www.youtube.com/channel/UCPZ8wdx5vOmvzdR3h5hFtNA", "hhttps://www.youtube.com/channel/UCPZ8wdx5vOmvzdR3h5hFtNA", "https://www.blogger.com/go/report-abuse", "https://www.blogger.com"]}